Search research articles
Contact Us
Filters
Showing results (321-330 of 346) with videos related to
Page
of 35
Sort By:
Theranostics
|
May 23, 2017
Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses
Michael Schmitt, Anita Schmitt, Markus Wiesneth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial
Markus Schaich, Stefani Parmentier, Michael Kramer, et al.
Frontiers in Immunology
|
October 24, 2018
Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects
Lei Wang, Ming Ni, Angela Hückelhoven-Krauss, et al.
European Journal of Haematology
|
April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE
Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Blood
|
December 8, 2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele, Michael Lauseker, Alois Gratwohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)
Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
British Journal of Haematology
|
January 16, 2016
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
Jan M Middeke, Sylvia Herold, Elke Rücker-Braun, et al.
Haematologica
|
August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
Sabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
Blood
|
March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 346) with videos related to
Sort By:
Page
of 35
Theranostics
|
May 23, 2017
Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses
Michael Schmitt, Anita Schmitt, Markus Wiesneth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial
Markus Schaich, Stefani Parmentier, Michael Kramer, et al.
Frontiers in Immunology
|
October 24, 2018
Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects
Lei Wang, Ming Ni, Angela Hückelhoven-Krauss, et al.
European Journal of Haematology
|
April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE
Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Blood
|
December 8, 2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele, Michael Lauseker, Alois Gratwohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)
Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
British Journal of Haematology
|
January 16, 2016
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
Jan M Middeke, Sylvia Herold, Elke Rücker-Braun, et al.
Haematologica
|
August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
Sabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
Blood
|
March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Page
of 35